Your email has been successfully added to our mailing list.

×
0 0 -0.0217142857142857 -0.0171428571428572 -0.00800000000000003 -0.0142628571428572 0.00228571428571424 0.00342857142857156
Stock impact report

Aldeyra sets sights on U.S. application for reproxalap in dry eye disease [Seeking Alpha]

Aldeyra Therapeutics, Inc. (ALDX) 
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aldeyra.com/investor-relations
Company Research Source: Seeking Alpha
Based on FDA feedback, Aldeyra Therapeutics (NASDAQ:ALDXlaunch two Phase 3 clinical trialsTopline results from the first Phase 3 should be available by year-end. A safety study should launch in Q4.If all goes according to plan, it will file an NDA in late 2021.On the working capital front, the company believes its current level of resources should be sufficient to fund operations into 2022.Shares up15% Show less Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ALDX alerts
Opt-in for
ALDX alerts

from News Quantified
Opt-in for
ALDX alerts

from News Quantified